Litigation Details for Genzyme Corporation v. Gland Pharma Limited (D. Del. 2018)
✉ Email this page to a colleague
Genzyme Corporation v. Gland Pharma Limited (D. Del. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-07-19 |
| Court | District Court, D. Delaware | Date Terminated | 2020-01-23 |
| Cause | 35:271 Patent Infringement | Assigned To | Kent A. Jordan |
| Jury Demand | None | Referred To | |
| Patents | 6,987,102; 7,897,590; RE42,152 | ||
| Link to Docket | External link to docket | ||
Details for Genzyme Corporation v. Gland Pharma Limited (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-07-19 | 1 | Complaint | the ’590 patent”), and 6,987,102 (“the ’102 patent”) arising under the Patent Laws of the United States…152 patent, the ’590 patent, and the ’102 patent based on Gland’s contention that the ’152 patent, the…is an action for patent infringement of U.S. Patent Nos. RE42,152 (“the ’152 patent”), 7,897,590 (“the…least some claims of the ’152 patent, the ’590 patent, and the ’102 patent. Moreover, Plaintiff Sanofi … The ’152 patent, the ’590 patent, and the ’102 patent cover the use of Mozobil® according to its Approved | External link to document |
| 2018-07-19 | 4 | Patent/Trademark Report to Commissioner of Patents | E; US 7,897,590 B2; US 6,987,102 B2. (ceg) (Entered: 07/19/2018) 19 July 2018 PACER Document … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US RE42,152 E;…2018 23 January 2020 1:18-cv-01071 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
